Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA and PAI-1 are associated with poor prognosis in breast cancer patients. To confirm the prognostic value of uPA and PAI-1 in primary breast cancer, we reanalyzed individual patient data provided by members of the European Organization for Research and Treatment of Cancer-Receptor and Biomarker Group (EORTC-RBG). METHODS: The study included 18 datasets involving 8377 breast cancer patients. During follow-up (median 79 months), 35% of the patients relapsed and 27% died. Levels of uPA and PAI-1 in tumor tissue extracts were determined by different immunoassays; values were ranked within each dataset and divided by the number of patients in that dataset to produce fractional ranks that could be compared directly across datasets. Associations of ranks of uPA and PAI-1 levels with relapse-free survival (RFS) and overall survival (OS) were analyzed by Cox multivariable regression analysis stratified by dataset, including the following traditional prognostic variables: age, menopausal status, lymph node status, tumor size, histologic grade, and steroid hormone-receptor status. All P values were two-sided. RESULTS: Apart from lymph node status, high levels of uPA and PAI-1 were the strongest predictors of both poor RFS and poor OS in the analyses of all patients. Moreover, in both lymph node-positive and lymph node-negative patients, higher uPA and PAI-1 values were independently associated with poor RFS and poor OS. For (untreated) lymph node-negative patients in particular, uPA and PAI-1 included together showed strong prognostic ability (all P<.001). CONCLUSIONS: This pooled analysis of the EORTC-RBG datasets confirmed the strong and independent prognostic value of uPA and PAI-1 in primary breast cancer. For patients with lymph node-negative breast cancer, uPA and PAI-1 measurements in primary tumors may be especially useful for designing individualized treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
The urokinase-type plasminogen activator system in cancer metastasis: A review
Andreasen, P. A., Kjøller, L., Christensen, L., & Duffy, M. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z · Cited by 1,546
Self-citationHorder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Early Breast Cancer Trialists’ Collaborative Group, & Peto, R. (1993) · Recent Results in Cancer Research · doi:10.1007/978-3-642-84745-5_21 · Cited by 958
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0898-923 · Cited by 677
Self-citationThe serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin
Stefansson, S., & Lawrence, D. A. (1996) · Nature · doi:10.1038/383441a0 · Cited by 674
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
Carmeliet, P., Moons, L., Lijnen, R., Baes, M., Lemaître, V., Tipping, P., Drew, A., Eeckhout, Y., Shapiro, S., Lupu, F., et al. (1997) · Nature Genetics · doi:10.1038/ng1297-439 · Cited by 661
Deng, G., Curriden, S. A., Wang, S., Rosenberg, S., & Loskutoff, D. J. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.6.1563 · Cited by 448
Janicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C. G. J. F., Selbmann, H.-K., Graeff, H., & Schmitt, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.12.913 · Cited by 434
Self-citationThe urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brünner, N., Jänicke, F., Gelder, M. E. M., Henzen-Logmans, S. C., et al. (2000) · PubMed · Cited by 419
Self-citationSchmitt, M., Harbeck, N., Thomssen, C., et al. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657541 · Cited by 386
Self-citationGrøndahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brünner, N., Mouridsen, H. T., Danø, K., & Blichert-Toft, M. (1993) · PubMed · Cited by 380
Self-citationProteases as prognostic markers in cancer.
Duffy, M. J. (1996) · PubMed · Cited by 316
Self-citationUrokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
Duffy, M. J., O'siorain, L., O'grady, P., Devaney, D., Fennelly, J. J., & Lijnen, H. J. (1988) · Cancer · doi:10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b · Cited by 282
Self-citationPrognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast Cancer
Desforges, J. F., McGuire, W. L., & Clark, G. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262607 · Cited by 282
Prognostic Factors and Therapeutic Decisions in Axillary Node-Negative Breast Cancer
Elledge, R. M., & McGuire, W. L. (1993) · Annual Review of Medicine · doi:10.1146/annurev.me.44.020193.001221 · Cited by 257
Gasparini, G., Pozza, F., & Harris, A. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.15.1206 · Cited by 238
Jänicke, F., Schmitt, M., & Graeff, H. (1991) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-1002624 · Cited by 227
Self-citationEppenberger, U., Kueng, W., Schlaeppi, J. M., Roesel, J. L., Benz, C., Mueller, H., Matter, A., Zuber, M., Luescher, K., Litschgi, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3129 · Cited by 218
Self-citationHayes, D. F., Trock, B., & Harris, A. L. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006197805041 · Cited by 184
Grebenschikov, N., Geurts-Moespot, A. J., de Witte, H., Heuvel, J. J. T. M., Leake, R. E., Sweep, F. C. G. J., & Benraad, T. J. (1997) · The International Journal of Biological Markers · doi:10.1177/172460089701200102 · Cited by 89
Harbeck, N., Thomssen, C., Berger, U., Ulm, K., Kates, R. E., Höfler, H., Jänicke, F., Graeff, H., & Schmitt, M. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006118828278 · Cited by 84
Self-citationMalmström, P., Bendahl, P.-O., Boiesen, P., Brünner, N., Idvall, I., & Fernö, M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.2010 · Cited by 75
Self-citationBenraad, T. J., Geurts-Moespot, J., Grøndahl-Hansen, J., Schmitt, M., Heuvel, J. J. T. M., Witte, J., Foekens, J. A., Leake, R. E., Brünner, N., & Sweep, F. C. G. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00118-9 · Cited by 69
Self-citationDuffy, M. J., Duggan, C. R., Mulcahy, H. E., McDermott, E. W. M., & O’Higgins, N. J. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.6.1177 · Cited by 62
Self-citationDissemination Risk Index Based on Plasminogen Activator System Components in Primary Breast Cancer
Bouchet, C., Hacène, K., Martin, P., Becette, V., Tubiana-Hulin, M., Lasry, S., Oglobine, J., & Spyratos, F. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3048 · Cited by 61
Self-citationGrøndahl-Hansen, J., Christensen, I. J., Briand, P., Pappot, H., Mouridsen, H. T., Blichert-Toft, M., Danø, K., & Brünner, N. (1997) · PubMed · Cited by 42
Self-citationBroët, P., Spyratos, F., Romain, S., Quillien, V., Daver, A., Ricolleau, G., Rallet, A., Toulas, C., & Asselain, B. J. R. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690389 · Cited by 29
Self-citationBouchet, C., Spyratos, F., Hacène, K., Durcos, L., Becette, V., & Oglobine, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.246 · Cited by 17
Self-citationModulators of the urokinase-type plasminogen activation system for cancer
Rosenberg, S. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.12.1843 · Cited by 11
Harrell, F., Jr. (1996) · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Cited by
Harbeck, N., & Gnant, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,280
Self-citationBreast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Meta-analysis of individual participant data: rationale, conduct, and reporting
Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010) · BMJ · doi:10.1136/bmj.c221 · Cited by 1,701
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Self-citation
Metadata
- Authors
- Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., Sweep, C. G. J. F., Ulm, K., Peyrat, J.-P., Martin, P.-M., Magdelenat, H., Brunner, N., Duggan, C., Lisboa, B. W., Bendahl, P.-O., Quillien, V., Daver, A., Ricolleau, G., Meijer-van Gelder, M. E., Manders, P., Fiets, W. E., Blankenstein, M. A., Broet, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borstnar, S., Kueng, W., Beex, L. V. A. M., Klijn, J. G. M., O'Higgins, N., Eppenberger, U., Janicke, F., Schmitt, M., & Foekens, J. A.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01-16
- Volume
- 94
- Issue
- 2
- Pages
- 116-128
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2150776809
- Cited by
- 596
- References
- 34
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.